Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review - Top-Institutions - MDSpire

Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review

  • By

  • Liu, Honglin

  • Zhang, Wei

  • May 5, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    our center
    our center

    Unknown, Unknown

    Key Differentiators

    • Pediatrics

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Cleveland Clinic Taussig Cancer Institute
    Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Case Comprehensive Cancer Center
    Case Comprehensive Cancer Center

    Cleveland, Ohio

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, Florida

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review

  • by Liu, Honglin , Zhang, Wei

  • May 5, 2026

Related Content

Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China

Reversibility of calcinosis in anti-NXP2-positive refractory dermatomyositis treated with TNF-α blockade: a brief report

Medical Oddities: Brain Health, Sunny-Side Up

Breakfast, bacteria, and brain wiring—small things show big implications this week.